Dabigatran etexilate is an oral direct thrombin inhibitor. It is rapidly converted by a serum esterase to dabigatran. It is an effective anticoagulant agent because direct thrombin inhibitors ...

In this post-hoc analysis of the RE-LY data set, the investigators simulated how dabigatran (n = 6,004) would compare to well-controlled warfarin (n = 6,022) used according to the EU label.

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...